Axogen, Inc. — Director's Dealing 2016

Aug 11, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AxoGen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2016-08-08

Reporting Person: Mandato Joseph M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-08	Common Stock	S	107450	$8.63	Disposed	1268941	Indirect
2016-08-09	Common Stock	S	42168	$8.30	Disposed	1226773	Indirect

Footnotes

F1: Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $8.50 and $8.67 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F2: The Form 4 filed with the SEC on June 3, 2015 over reported the amount of securities beneficially owned following the reported transaction by one share, which has been corrected in this filing.

F3: The shares are owned by De Novo Ventures II, L.P. ("DNV II"). De Novo Management II, LLC is the sole general partner of DNV II. The reporting person is a managing member of De Novo Management II, LLC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F4: Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $8.27 and $8.34 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.